The impact of network biology in pharmacology and toxicology

SAR and QSAR in Environmental Research

Volumn 23, Issue 3-4, 2012, Pages 221-235

  Panagiotou, G ^a,b   Taboureau, O ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b Chalmers University of Technology   (Denmark)

Author keywords

chemical biology; chemical toxicity; network biology; systems biology

Indexed keywords

TOXICITY;

CHEMICAL BIOLOGY; CHEMICAL TOXICITY; DRUG DISCOVERY; DRUG EFFECTS; DRUG EFFICACY; EMERGING TECHNOLOGIES; NETWORK BIOLOGY; PHYSIOLOGICAL ENVIRONMENT; PROTEIN FUNCTIONS; SYSTEMS BIOLOGY;

MOLECULES;

EID: 84860296344     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2012.657237     Document Type: Review

References (86)

1. Villoslada, P, Steinman, L and Baranzini, SE. 2009. Systems biology and its application to the understanding of neurological diseases. Ann. Neurol., 65: 124-139.
2. Wang, K, Le, I, Carlson, G, Hood, L and Galas, D. 2010. Systems biology and the discovery of diagnostic biomarkers. Dis. Markers, 28: 199-207.
3. Chautard, E, Thierry-Mieg, N and Ricard-Blum, S. 2009. Interaction networks: From protein functions to drug discovery. A review. Pathol. Biol., 57: 324-333.
4. Berger, SI and Iyengar, R. 2009. Network analyses in systems pharmacology. Bioinformatics, 25: 2466-2472.
5. Schadt, EE, Zhang, B and Zhu, J. 2009. Advances in systems biology are enhancing our understanding of disease and moving us closer to novel disease treatments. Genetics, 136: 259-269.
6. Iorio, F, Tagliaferri, R and di Bernardo, D. 2009. Identifying network of drug mode of action by gene expression profiling. J. Comput. Biol., 16: 241-251.
7. Li, J, Zhu, X and Chen, JY. 2009. Building disease specific drug protein connectivity maps from molecular interaction networks and PubMed abstracts. PLoS Comput. Biol., 5: e1000450
8. Chen, B, Wild, D and Guha, R. 2009. PubChem as a source of polypharmacology. J. Chem. Inf. Model., 49: 2044-2055.
9. Chandra, N. 2009. Computational systems approach for drug target discovery. Exp. Opin. Drug Discov., 4: 1221-1236.
10. Pawson, T and Linding, R. 2008. Network Medicine. FEBS Lett., 582: 1266-1270.
11. Kutalik, Z, Beckmann, JS and Bergmann, S. 2008. A modular approach for integrative analysis of large scale gene expression and drug response data. Nat. Biotechnol., 26: 531-539.
12. Wu, Z, Zhao, XM and Chen, L. 2010. A systems biology approach to identify effective cocktail drugs. BMC Syst. Biol., 4: 57-71.
13. Schadt, EE, Friend, SH and Shaywitz, DA. 2009. A network view of disease and compound screening. Nat. Rev. Drug Discov., 8: 286-295.
14. Florez, AF, Park, D, Bhak, J, Kim, BC, Kuchinsky, A, Morris, JH, Espinosa, J and Muskus, C. 2010. Protein network prediction and topological analysis in Leishmania major as a tool for drug discovery target selection. BMC Bioinformatics, 11: 484-494.
15. Chen, X, Xu, J, Huang, B, Li, J, Wu, X, Ma, L, Jia, X, Bian, X, Tan, F, Liu, L, Chen, S and Li, X. 2011. A sub-pathway-based approach for identifying drug response principal network. Bioinformatics, 27: 649-654.
16. Iorio, F, Boscotti, R, Scacheri, E, Belcastro, V, Mithbaokar, P, Ferriero, R, Murino, L, Tagliaferri, R, Brunetti-Pierri, N, Isaachi, A and di Bernardo, D. 2010. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. U S A, 107: 14621-14626.
17. st century. ALTEX, 28: 17-44.
18. Morrow, JK, Tian, L and Zhang, S. 2010. Molecular networks in drug discovery. Crit. Rev. Biomed. Eng., 38: 143-156.
19. Mendrick, DL. 2011. Transcriptional profiling to identify biomarkers of disease and drug response. Pharmacogenomics, 12: 235-249.
20. Hartwell, LH, Hopfield, JJ, Leiber, S and Murray, AW. 1999. From molecular to modular cell biology. Nature, 402: 47-52.
21. Sharan, R, Ulitsky, I and Shamir, R. 2007. Network-based prediction of protein function. Mol. Syst. Biol., 3: 88
22. Graul, AI, Revel, L, Tell, M, Rosa, E and Cruces, E. 2010. Overcoming the obstacles in the pharma-biotech industry: 2009 update. Drug News Perspect., 23: 48-63.
23. Lahana, R. 2003. Who wants to be irrational?. Drug Discov. Today, 8,: 655-656.
24. Garnier, J. 2008. Rebuilding the R&D engine in big pharma. Harvard Bus. Rev., 86: 68-76.
25. Paul, SM, Mytelka, DS, Dunwiddie, CT, Persinger, CC, Munos, BH, Lindborg, SR and Schacht, AL. 2010. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev. Drug Discov., 9: 203-214.
26. Fox, S, Farr-Jones, S, Sopchak, L, Boggs, A, Nicely, HW, Khoury, R and Biros, M. 2006. High throughput screening: Update on practices and success. J. Biomol. Screen., 11: 864-869.
27. Bickle, M. 2010. The beautiful cell: High content screening in drug discovery. Anal. Bioanal. Chem., 398: 219-226.
28. Kool, J, Lingeman, H, Niessen, W and Irth, H. 2010. High throughput screening methodologies classified for major drug target classes according to target signalling pathways. Comb. Chem. High Throughput Screen., 13: 548-561.
29. Hajduk, PJ and Greer, J. 2007. A decade of fragment based drug design: Strategic advances and lessons learned. Nat. Rev. Drug Discov., 6: 211-219.
30. Michelini, E, Cevenini, L, Mezzanotte, L, Coppa, A and Roda, A. 2010. Cell-based assays: Fuelling drug discovery. Anal. Bioanal. Chem., 398: 227-238.
31. Crews, CM. 2010. Targeting the undruggable proteome: The small molecules of my dreams. Chem. Biol., 17: 551-555.
32. Coma, I, Clark, L, Diez, E, Harper, G, Herranz, J, Hofmann, G, Lennon, M, Richmond, N, Valmasea, M and Macarron, R. 2009. Process validation and screen reproducibility in high throughput screening. J. Biomol. Screen., 7: 554-569.
33. Snowden, M and Green, DV. 2008. The impact of diversity based high throughput screening on drug discovery: "chance favours the prepared mind". Curr. Opin. Drug Discov. Devel., 11: 553-558.
34. Mayr, LM and Bojanic, D. 2009. Novel trends in high throughput screening. Curr. Opin. Pharmacol., 9: 580-588.
35. Kaiser, J. 2008. Industrial style screening meets academic biology. Science, 321: 764-766.
36. Silber, BM. 2010. Driving drug discovery: The fundamental role of academic labs. Sci. Transl. Med, 2: 30-46.
37. Wheeler, DL, Barrett, T, Benson, DA, Bryant, SH, Canese, K, Chetvernin, V, Church, DM, DiCuccion, M, Edgar, R, Federhen, S, Feolo, M, Geer, LY, Helmberg, W, Kapustin, Y, Khovayko, O, Landsman, D, Lipman, DJ, Madden, TL, Maglott, DR, Miller, V, Ostell, J, Pruitt, KD, Schuler, GD, Shumway, M, Sequeira, E, Sherry, ST, Sirotkin, K, Souvorov, A, Starchenko, G, Tatusov, GRL, Tatusova, TA, Wagner, L and Yaschenko, E. 2007. Database resources of the National Center for Biotechnology Information. Nucleic Acid Res., 35: D5-D12.
38. Seiler, KP, George, GA, Happ, MP, Bodycombe, NE, Carrinski, HA, Norton, S, Brudz, S, Sullivan, JP, Muhlich, J, Serrano, M, Ferraiolo, P, Tolliday, NJ, Schreiber, SL and Clemons, PA. 2008. Chembank: A small-molecule screening and chemoinformatics resource database. Nucleic Acid Res., 36: D351-D359.
39. Gaulton, A, Bellis, LJ, Bento, AP, Chambers, J, Davies, M, Hersey, A, Light, Y, McGlinchey, S, Michalovitch, D, Al-Lazikani, B and Overnigton, JP. ChEMBL: a large-scale bioactivity database for drug discovery, Nucleic Acids Res. (2011), Epub ahead of print
40. Bellis, LJ, Akhtar, R, Al-Lazikani, B, Atkinson, F, Bento, AP, Chambers, J, Davies, M, Gaulton, A, Hersey, A, Ikeda, K, Krüger, FA, Light, Y, McGlinchey, S, Santos, R, Stauch, B and Overington, JP. 2011. Collation and data-mining of literature bioactivity data for drug discovery. Biochem. Soc. Trans., 39: 1365-1370.
41. Liu, T, Lin, Y, Wen, X, Jorissen, RN and Gilson, MK. 2007. BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res., 35: D198-D201.
42. Kanehisa, M, Goto, S, Hattori, M, Aoki-Kinoshita, KF, Itoh, M, Kawashima, S, Katayama, T, Araki, M and Hirakawa, M. 2006. From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res., 34: 354-357.
43. Kuhn, M, Campillos, M, Letunic, I, Jensen, LJ and Bork, P. 2010. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol., 6: 343
44. Judson, R, Richard, A, Dix, D, Houck, K, Elloumi, F, Martin, M, Cathey, T, Transue, TR, Spencer, R and Wolf, M. 2008. ACToR-Aggregated computational toxicology resource. Toxicol. Appl. Pharmacol., 233: 7-13.
45. Dailymed, available athttp://dailymed.nlm.nih.gov/dailymed/
46. Toxnet, available athttp://toxnet.nlm.nih.gov/
47. Campillos, M, Kuhn, M, Gavin, AC, Jensen, LJ and Bork, P. 2008. Drug target identification using side-effect similarity. Science, 321: 263-266.
48. Garcia-Serra, R and Mestres, J. 2010. Anticipating drug side effects by comparative pharmacology. Expert Opin. Drug Metab. Toxicol., 6: 1253-1263.
49. Pouliot, Y, Chiang, AP and Butte, AJ. 2011. Predicting adverse drug reactions using publicly available PubChem bioassay data. Clin. Pharmacol. Ther., 90: 90-99.
50. Smith, DA, Harrison, A and Morgan, P. 2011. Multiple factors govern the association between pharmacology and toxicity in a class of drugs: Toward a unification of class effect terminology. Chem. Res. Toxicol., 24: 463-474.
51. Elangbam, CS, Job, LE, Zadrozny, LM, Arton, JC, Yoon, LW, Gates, LD and Slocum, N. 2008. 5-hydroxytryptamine (5HT)-induced valvulopathy: Compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp. Toxicol. Pathol., 60: 253-262.
52. Oprea, TI, Nielsen, SK, Ursu, O, Yang, JJ, Taboureau, O, Mathias, SL, Kouskoumvekaki, I, Sklar, LA and Bologa, CG. 2011. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol. Inf., 30: 100-111.
53. Schena, M, Shalon, D, Davis, RW and Brown, PO. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 270: 467-470.
54. Dennis, G, Sherman, BT, Hosack, DA, Yang, J, Gao, W, Lane, HC and Lempicki, RA. 2003. DAVID: Database for annotation, visualization, and integrated discovery. Genom. Biol., 4: R60
55. Severgnini, M, Bicciato, S, Mangano, E, Scarlatti, F, Mezzelani, A, Mattioli, M, Ghidoni, R, Peano, C, Bonnal, R, Viti, F, Milanesi, L, De Bellis, G and Battaglia, C. 2006. Strategies for comparing gene expression profiles from different microarray platforms: Application to a case-control experiment. Anal. Bio. Chem., 353: 43-56.
56. Barrett, T, Troup, DB, Wilhite, SE, Ledoux, P, Evangelista, C, Kim, IF, Tomashevsky, M, Marshall, KA, Phillippy, KH, Sherman, PM, Muertter, RN, Holko, M, Ayanbule, O, Yefanov, A and Soboleva, A. 2011. NCBI GEO: Archive for functional genomics data sets-10 years now. Nucleic Acids Res., 39: D1005-D1010.
57. Baron, D, Dubois, E, Bihouee, A, Teusan, R, Steenman, M, Jourdon, P, Magot, A, Pereon, Y, Veitia, R, Savagner, F, Ramstein, G and Houlgatte, R. 2011. Meta-analysis of muscle transcriptome data using the MADMuscle database reveals biologically relevant gene patterns. BMC Genomics, 12: 113
58. McCall, MN, Uppal, K, Jaffee, HA, Zilliox, MJ and Irizarry, RA. 2011. The Gene Expression Barcode: Leveraging public data repositories to begin cataloging the human and murine transcriptomes. Nucleic Acids Res., 39: D1011-D1015.
59. Xiao, SJ, Zhang, C, Zou, Q and Ji, ZL. 2010. TiSGeD: A database for tissue specific genes. Bioinformatics, 26: 1273-1275.
60. Vazquez, M, Nogales-Cadenas, R, Arroyo, J, Botias, P, Garcia, R, Carazo, JM, Tirado, F, Pascual-Montano, A and Carmona-Saez, P. 2010. MARQ: An online tool to mine GEO for experiments with similar or opposite gene expression signatures. Nucleic Acids Res., 38: W228-W232.
61. Lamb, J, Crawford, ED, Peck, D, Modell, JW, Blat, IC, Wrobel, MJ, Lemer, J, Brunet, JP, Subramanian, A, Ross, KN, Reich, M, Hieronymous, H, Wei, G, Armstrong, SA, Lander, ES and Golub, TR. 2006. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science, 313: 1929-1935.
62. Camon, E, Magrane, M, Barrell, D, Lee, V, Dimmer, E, Maslen, J, Binns, D, Harte, N, Lopez, R and Apweiler, R. 2004. The gene ontology annotation (GOA) database-sharing knowledge in Uniprot with gene ontology. Nucleic Acids Res., 32: D262-D266.
63. Joshi-Tope, G, Gillespie, M, Vastrik, I, D'Eustachio, P, Schmidt, E, de Bono, B, Jassal, B, Gopinath, GR, Wu, GR, Matthews, L, Lewis, S, Birney, E and Stein, L. 2005. Reactome: A knowledgebase of biological pathways. Nucleic Acids Res., 33: 428-432.
64. Hamosh, A, Scott, AF, Amberger, JS, Bocchini, CA and McKusick, VA. 2005. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res., 33: 514-517.
65. Huang, DW, Sherman, BT and Lempicki, RA. 2009. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res., 37: 1-13.
66. Kiyosawa, N, Ando, Y, Manabe, S and Yamoto, T. 2009. Toxicogenomics biomarkers for liver toxicity. J. Toxicol. Pathol., 22: 35-52.
67. Iskar, M, Campillos, M, Kuhn, M, Jensen, LJ, van Noort, V and Bork, P. 2010. Drug-induced regulation of target expression. PLoS Comput. Biol., 6: e1000925
68. Nitsch, D, Tranchevent, LC, Goncalves, JP, Vogt, JK, Madeira, SC and Moreau, Y. 2011. PINTA: A web server for network-based gene prioritization from expression data. Nucleic Acids. Res., 39: 334-338.
69. Köhler, S, Bauer, S, Horn, D and Robinson, PN. 2008. Walking the interactome for prioritization of candidate disease genes. Am. J. Hum. Genet., 82: 949-958.
70. Tranchevent, LC, Capdevila, FB, Nitsch, D, De Moor, B, De Causmæcker, P and Moreau, Y. 2010. A guide to web tools to prioritize candidate genes. Brief. Bioinf., 12: 22-32.
71. Boverhof, DR and Zacharewski, TR. 2006. Toxicogenomics in risk assessment: Applications and needs. Toxicol. Sci., 89: 352-360.
72. Wilson, VS, Keshava, N, Hester, S, Segal, D, Chiu, W, Thompson, CM and Euling, SY. Utilizing toxicogenomics data to understand chemical mechanism of action in risk assessment, Toxicol. Appl. Pharmacol. (2011), Epub ahead of print
73. Yildirim, MA, Goh, KI, Cusick, ME, Barabasi, AL and Vidal, M. 2007. Drug-target network. Nat. Biotechnol., 25: 1119-1126.
74. Kuhn, M, von Mering, C, Campillos, M, Jensen, LJ and Bork, P. 2008. STITCH: Interaction networks, of chemicals and proteins. Nucleic Acids Res., 36: D684-D688.
75. Kuhn, M, Szlarczyk, D, Franceschini, A, Campillos, M, von Mering, C, Jensen, LJ, Beyer, A and Bork, P. 2010. STITCH2: An interaction network database for small molecules and proteins. Nucleic Acids Res., 38: D552-D556.
76. von Mering, C, Jensen, LJ, Snel, B, Hooper, SD, krupp, M, Foglierini, M, jouffre, N, Huynen, MA and Bork, P. 2005. STRING: Known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res., 33: D433-D437.
77. Taboureau, O, Nielsen, SK, Audouze, K, Weinhold, N, Edsgärd, D, Roque, FS, Kouskoumvekaki, I, Bora, A, Curpan, R, Jensen, TS, Brunak, S and Oprea, TI. 2011. ChemProt: A disease chemical biology database. Nucleic Acids Res., 39: D367-D372.
78. Lage, K, Karlberg, EO, Størling, ZM, Olason, PI, Pedersen, AG, Rigina, O, Hinsby, AM, Tümer, Z, Pociot, F, Tommerup, N, Moreau, Y and Brunak, S. 2007. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat. Biotechnol., 25: 309-316.
79. Fernald, GH, Capriotti, E, Daneshjou, R, Karczewski, KJ and Altman, RB. 2011. Bioinformatics challenges for personalized medicine. Bioinformatics, 27: 1741-1748.
80. Sherry, ST, Ward, MH, Kholodov, M, Baker, J, Phan, L, Smigielski, EM and Sirotkin, K. 2001. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res., 29: 308-311.
81. Sayers, EW, Barrett, T, Benson, DA, Bolton, E, Bryant, SH, Canese, K, Chetvernin, V, Church, DM, Dicuccio, M, Federhen, S, Feolo, M, Fingerman, IM, Geer, LY, Helmberg, W, Kapustin, Y, Landsman, D, Lipman, DJ, Lu, Z, Madden, TL, Madej, T, Maglott, DR, Marchler-Bauer, A, Miller, V, Mizrachi, I, Ostell, J, Panchenko, A, Phan, L, Pruitt, KD, Schuler, GD, Sequeira, E, Sherry, ST, Shumway, M, Sirotkin, K, Slotta, D, Souvorov, A, Starchenko, G, Tatusova, TA, Wagner, L, Wang, Y, Wilbur, WJ, Yaschenko, E and Ye, J. 2011. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res., 39: 38-51.
82. Levy, S, Sutton, G, Ng, PC, Feuk, L, Halpern, AL, Walenz, BP, Axelrod, N, Huang, J, Kirkness, EF, Denisov, G, Lin, Y, MacDonald, JR, Pang, AW, Shago, M, Stockwell, TB, Tsiamouri, A, Bafna, V, Bansal, V, Kravitz, SA, Busam, DA, Beeson, KY, McIntosh, TC, Remington, KA, Abril, JF, Gill, J, Borman, J, Rogers, YH, Frazier, ME, Scherer, SW, Strausberg, RL and Venter, JC. 2007. The diploid genome sequence of an individual human. PLoS Biol., 5: e254
83. Hindorff, LA, Sethupathy, P, Junkins, HA, Ramos, EM, Mehta, JP, Collins, FS and Manolio, TA. 2009. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. U S A, 106: 9362-9367.
84. Hansen, NT, Brunak, S and Altman, RB. 2009. Generating genome-scale candidate gene lists for pharmacogenomics. Clin. Pharmacol Ther., 86: 183-189.
85. Chen, L, Zhang, L, Zhao, Y, Xu, L, Shang, Y, Wang, Q, Li, W, Wang, H and Li, X. 2009. Prioritizing risk pathways: A novel association approach to searching for disease pathways fusing SNPs and pathways. Bioinformatics, 25: 237-242.
86. O'Dushlaine, C, Kenny, E, Heron, EA, Segurado, R, Gill, M, Morris, DW and Corvin, A. 2009. The SNP ratio test: Pathway analysis of genome-wide association datasets. Bioinformatics, 25: 2762-2763.